Project Grant R44CA295167
Award Date
8/13/24
Completion Date
7/31/26
Dollars Obligated
$2M
Federal Agency
National Cancer Institute
Awardee
Sonoval LLC (QEWBWHSG1GH9)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
The National Cancer Institute (NCI) awarded Celdara Medical, LLC a $1,024,967 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The goal is to advance CM-HZ01 to Investigational New Drug (IND) status, providing a potentially best-in-class immunotherapy option for patients with limited effective treatments for this deadly form of skin cancer. The project period runs from January...
The National Cancer Institute (NCI) awarded a $798,512 Project Grant under CFDA 93.395 - Cancer Treatment Research to Luminary Therapeutics, Inc., a small disadvantaged business, to develop an allogeneic gamma/delta armored dual-targeting chimeric antigen receptor (CAR) T-cell therapy to treat epithelial ovarian carcinoma. The project aims to address key challenges with CAR T-cell therapies against solid tumors, including antigen escape and the immunosuppressive tumor microenvironment, through...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded a $3,157,784 Project Grant to Synthis Therapeutics, Inc. to conduct in vivo efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) analysis of SYN101, a first-in-class immune cell-targeted TGFβ therapy for cancer patients. The goals of the 22-month project are to: 1) test the efficacy of SYN101 in humanized mouse tumor models and define the comprehensive immune response, and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The award of $1,001,029.00 will fund the generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, as well as the determination of its pharmacokinetics, biodistribution, and toxicity. This work aims to accelerate the...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), awarded a $999,960 Project Grant to Linnaeus Therapeutics Inc. on January 13, 2025. The purpose of this grant is to expand upon preliminary clinical data and complete a proof-of-concept study of the drug candidate LNS8801 for treating melanoma patients who cannot tolerate immunotherapy due to immune-related adverse events. LNS8801 is an orally deliverable small molecule that targets the G...
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), awarded a $400,000 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc. on September 19, 2024. The goal of this STTR project is to develop an RNA interference-based therapeutic to treat prostate cancer. The therapeutic, termed "NU002", will use lipopolyplex nanoparticles to deliver short interfering RNAs (siRNAs) derived from CAG trinucleotide repeat sequences....
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Promilead, LLC to evaluate a small-molecule compound, USCYL01, as a potential therapy to enhance the efficacy of immune checkpoint inhibitors (ICIs) for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) assess the toxicity and pharmacokinetic properties of USCYL01 in vitro and in vivo, and 2) test USCYL01 as an adjunct to ICI plus...